This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the standard of care and the recent Phase 1 data presented by Novo Nordisk for their novel oral agent, amycretin
Ticker(s): NVOWho's the expert?
Institution: University of Texas Medical Branch
- Associate Director, Endocrinology Fellowship Program, Asst Prof (N-T Trk Clin), Internal medicine at UTMB.
- Treats 600 patients with Type-2 Diabetes.
Interview GoalThis interview will focus on discussing the standard of care and the recent Phase 1 data presented by Novo Nordisk for their novel oral agent, amycretin, which showed a 13.1% weight loss in patients after just 12 weeks.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
